Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 227,741,320 papers from all fields of science
Search
Sign In
Create Free Account
Antibody-drug Conjugate ADCT-402
Known as:
ADC ADCT-402
, ADCT-402
, Anti-CD19 PBD-conjugate ADCT-402
An antibody-drug conjugate (ADC) consisting of an anti-CD19 humanized monoclonal antibody conjugated, via a cleavable linker comprised of valine…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
NCIt Antineoplastic Agent Terminology
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Treatment of relapsed/refractory acute lymphoblastic leukemia.
Shilpa Paul
,
C. Rausch
,
Patrice Nasnas
,
H. Kantarjian
,
E. Jabbour
Clinical advances in hematology & oncology : H&O
2019
Corpus ID: 108293294
Patients with relapsed or refractory acute lymphoblastic leukemia (R/R ALL) have dismal outcomes, with survival of less than 6…
Expand
2019
2019
ANALYSIS OF EFFICACY AND SAFETY OF LONCASTUXIMAB TESIRINE (ADCT‐402) BY DEMOGRAPHIC AND CLINICAL CHARACTERISTICS IN RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA
J. Radford
,
B. Kahl
,
+11 authors
P. Caimi
Hematological Oncology
2019
Corpus ID: 196537861
refractory to prior therapy. CRS (according to the criteria by Lee et al. Blood 2014) occurred in 45 patients (23% G1, 24% G2, 3…
Expand
2019
2019
Investigational Drug Shows Promise in Diffuse Large B-Cell Lymphoma
Seth Augenstein
2019
Corpus ID: 228554854
A new investigational drug called ADCT-402 that combines a cell-killing compound with a monoclonal antibody shows early promise…
Expand
2018
2018
Interim Results from the First-in-Human Clinical Trial of Adct-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory Diffuse Large B-Cell…
J. Radford
,
B. Kahl
,
+11 authors
O. O’Connor
Blood
2018
Corpus ID: 59264485
Introduction: Diffuse large B-cell lymphoma (DLBCL) represents 33% of the non-Hodgkin lymphomas (NHL) and expresses CD19, a…
Expand
2018
2018
Safety and Efficacy of Adct-402 (Loncastuximab Tesirine), a Novel Antibody Drug Conjugate, in Relapsed/Refractory Follicular Lymphoma and Mantle Cell Lymphoma: Interim Results from the Phase 1 First…
P. Caimi
,
B. Kahl
,
+9 authors
O. O’Connor
Blood
2018
Corpus ID: 59254600
Introduction: CD19, a B-cell surface antigen, is overexpressed in neoplastic lymphoid cells. ADCT-402 (loncastuximab tesirine…
Expand
2017
2017
Interim Data from a Phase 1 Study Evaluating Pyrrolobenzodiazepine-Based Antibody Drug Conjugate ADCT-402 (Loncastuximab Tesirine) Targeting CD19 for Relapsed or Refractory B-Cell Acute Lymphoblastic…
N. Jain
,
R. Klisovic
,
+10 authors
M. Wieduwilt
2017
Corpus ID: 201965267
Introduction: Outcomes of patients with relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL) remain dismal…
Expand
2017
2017
Encouraging Early Results from the First in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory B-Cell…
B. Kahl
,
M. Hamadani
,
+11 authors
O. O’Connor
2017
Corpus ID: 80447878
Introduction : CD19 is expressed on the cell surface of many types of non-Hodgkin lymphoma (NHL), including follicular lymphoma…
Expand
2017
2017
FIRST CLINICAL RESULTS OF ADCT‐402, A NOVEL PYRROLOBENZODIAZEPINE‐BASED ANTIBODY DRUG CONJUGATE (ADC), IN RELAPSED/REFRACTORY B‐CELL LINEAGE NHL
Brad S. Kahl
,
M. Hamadani
,
+5 authors
Owen A. O'Connor
2017
Corpus ID: 80117452
2016
2016
A phase 1 adaptive dose-escalation study to evaluate the tolerability, safety, pharmacokinetics, and antitumor activity of ADCT-402 in patients with relapsed or refractory B-cell lineage non Hodgkin…
K. Chung
,
M. Hamadani
,
+4 authors
O. O’Connor
2016
Corpus ID: 81289726
TPS7580Background: In normal human tissue, expression of cluster of differentiation 19 (CD19) is limited to the developmental…
Expand
2015
2015
Pre-Clinical Development of Adct-402, a Novel Pyrrolobenzodiazepine (PBD)-Based Antibody Drug Conjugate (ADC) Targeting CD19-Expressing B-Cell Malignancies
F. Zammarchi
,
David G. Williams
,
+6 authors
P. V. Berkel
2015
Corpus ID: 79166214
Human CD19 antigen is a 95 kilodalton type I transmembrane glycoprotein belonging to the immunoglobulin superfamily (Wang, Wei…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE